This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoshimoto, T. Articles by Abe, H. Search for Related Content PubMed PubMed Citation Articles by Yoshimoto, T. Articles by Abe, H. Pubmed/NCBI databases Substance via MeSH

(Stroke. 1996;27:2160-2165.)
© 1996 American Heart Association, Inc.

Articles

Angiogenic Factors in Moyamoya Disease

Tetsuyuki Yoshimoto, MD; Kiyohiro Houkin, MD; Akihiro Takahashi, MD Hiroshi Abe, MD

the Department of Neurosurgery, Hokkaido University School of Medicine, Sapporo, Japan.

Correspondence to Tetsuyuki Yoshimoto, MD, Department of Neurosurgery, Hokkaido University School of Medicine, N-15, W-7, Kita-ku, Sapporo 060, Japan.

Background and Purpose We previously reported that the level of basic fibroblast growth factor (bFGF) is high in cerebrospinal fluid (CSF) taken from patients with moyamoya disease. The present study investigated the levels of other angiogenic growth factors in the CSF of moyamoya patients and the clinical significance of bFGF in moyamoya disease.

Methods The levels of bFGF, interleukin-8, platelet-derived growth factor, transforming growth factor-ß, endothelial growth factor, and vascular endothelial cell growth factor in CSF, taken from 38 patients with moyamoya disease and 16 patients with atherosclerotic occlusive disease (control group), were measured by an enzyme-linked immunosorbent assay. We analyzed the correlation between the level of bFGF and the clinical factors of age, onset pattern, development of neovascularization, and cerebral circulation.

Results The CSF of moyamoya patients contained a high concentration of bFGF to a significant (P<.05) extent. The bFGF level was apparently elevated in the patients in whom neovascularization from indirect revascularization, such as encephaloduroarteriosynangiosis, was well developed (P<.01). A linear correlation between the values of bFGF and cerebral vascular response to acetazolamide (r=.7; P<.05) was revealed. The other angiogenic factors were not significantly high compared with the control group.

Conclusions The elevation of bFGF in moyamoya disease seems to be specific and is not related simply to cerebral ischemia. Clinically, the bFGF level is a useful indicator to predict the efficacy of indirect revascularization after surgery.

Key Words: angiogenesis • cytokines • moyamoya disease

This article has been cited by other articles:

				S. Kuriyama, Y. Kusaka, M. Fujimura, K. Wakai, A. Tamakoshi, S. Hashimoto, I. Tsuji, Y. Inaba, and T. Yoshimoto Prevalence and Clinicoepidemiological Features of Moyamoya Disease in Japan: Findings From a Nationwide Epidemiological Survey Stroke, January 1, 2008; 39(1): 42 - 47. [Abstract] [Full Text] [PDF]

				G. A. Kerchner, W. Smith, M. T. Lawton, and V. Singh Co-occurrence of a cavernous malformation and contralateral moyamoya Neurology, May 23, 2006; 66(10): 1601 - 1602. [Full Text] [PDF]

				R. Nanba, S. Kuroda, T. Ishikawa, K. Houkin, and Y. Iwasaki Increased Expression of Hepatocyte Growth Factor in Cerebrospinal Fluid and Intracranial Artery in Moyamoya Disease Stroke, December 1, 2004; 35(12): 2837 - 2842. [Abstract] [Full Text] [PDF]

				S.-K. Kim, J.-I. Yoo, B.-K. Cho, S. J. Hong, Y.-K. Kim, J.-A. Moon, J. H. Kim, Y.-N. Chung, and K.-C. Wang Elevation of CRABP-I in the Cerebrospinal Fluid of Patients With Moyamoya Disease Stroke, December 1, 2003; 34(12): 2835 - 2841. [Abstract] [Full Text] [PDF]

				A. Kassner, X.-P. Zhu, K.-L. Li, and A. Jackson Neoangiogenesis in Association with Moyamoya Syndrome Shown by Estimation of Relative Recirculation based on Dynamic Contrast-Enhanced MR Images AJNR Am. J. Neuroradiol., May 1, 2003; 24(5): 810 - 818. [Abstract] [Full Text] [PDF]

				M. Soderman, G. Rodesch, and P. Lasjaunias Transdural Blood Supply to Cerebral Arteriovenous Malformations Adjacent to the Dura Mater AJNR Am. J. Neuroradiol., September 1, 2002; 23(8): 1295 - 1300. [Abstract] [Full Text] [PDF]

				M. Bonduel, M. Hepner, G. Sciuccati, A. F. Torres, S. Tenembaum, and G. de Veber Prothrombotic Disorders in Children With Moyamoya Syndrome Editorial Comment Stroke, August 1, 2001; 32(8): 1786 - 1792. [Abstract] [Full Text] [PDF]

				D. Chiu, P. Shedden, P. Bratina, and J. C. Grotta Clinical Features of Moyamoya Disease in the United States Stroke, July 1, 1998; 29(7): 1347 - 1351. [Abstract] [Full Text] [PDF]

				M. Yamamoto, M. Aoyagi, N. Fukai, Y. Matsushima, and K. Yamamoto Differences in Cellular Responses to Mitogens in Arterial Smooth Muscle Cells Derived From Patients With Moyamoya Disease Stroke, June 1, 1998; 29(6): 1188 - 1193. [Abstract] [Full Text] [PDF]

				M. Yamamoto, M. Aoyagi, S. Tajima, H. Wachi, N. Fukai, Y. Matsushima, and K. Yamamoto Increase in Elastin Gene Expression and Protein Synthesis in Arterial Smooth Muscle Cells Derived From Patients with Moyamoya Disease Stroke, September 1, 1997; 28(9): 1733 - 1738. [Abstract] [Full Text]